China has lifted its 30% import tax on Indian pharmaceuticals, enabling Indian drug makers to sell their products duty-free in the Chinese market. The move, announced after the United States imposed a 100% levy on pharmaceutical imports, marks a major shift in the global pharmaceutical trade and opens new opportunities for India’s exporters.
For Indian pharmaceutical companies, the timing is critical. The U.S. has long been a primary destination for India’s $25 billion-plus medicine export sector, particularly for low-cost generic drugs. Rising trade restrictions in Washington now threaten market access and profitability. China’s decision provides an alternative, giving Indian producers access to the world’s second-largest pharmaceutical market, home to a growing population and expanding healthcare needs.
India has long been regarded as the “pharmacy of the world,” supplying cost-effective generics and vaccines that fill vital gaps in global health infrastructure. High import duties in China had previously limited Indian firms’ competitiveness, but the removal of tariffs now allows them to compete on equal footing with both domestic and international players. Industry experts expect exports to China to rise significantly, potentially unlocking billions of dollars in additional trade.
The implications extend beyond commerce. Increased demand is likely to drive manufacturing growth in India, creating thousands of jobs across pharmaceutical plants, supply chains, and logistics. The shift also has the potential to rebalance India-China trade relations, which historically have tilted in Beijing’s favor, while bolstering resilience in global supply chains for essential medicines.
Analysts say the removal of tariffs could reshape international pharmaceutical trade by accelerating India’s integration into China’s healthcare market at a time when global protectionist measures are rising. With the U.S. closing its doors, India’s expanding presence in China strengthens its influence in the sector, enhances medicine access for millions, and consolidates its position as a global leader in affordable healthcare.
ORGANIZATIONS NEWS | SIRA, Germany Partner for Advanced Dual-Use Goods Control Training
